Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore. [electronic resource]
Producer: 20200819Description: 4985-4992 p. digitalISSN:- 1557-3265
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Biomarkers, Tumor
- Breast Neoplasms -- drug therapy
- Chemotherapy, Adjuvant
- Combined Modality Therapy
- Disease Progression
- Female
- Humans
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Metastasis
- Neoplasm Staging
- Neoplasm, Residual -- metabolism
- Netherlands
- Receptor, ErbB-2 -- metabolism
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.